ArticleBMC public health2024
Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030.
Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radicality and safety of total mesopancreatic excision in pancreatoduodenectomy: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- In silico discovery of RIOK3 inhibitors against pancreatic ductal adenocarcinoma using homology modelling, molecular docking, molecular dynamics simulations, ADMET prediction, and MTT assay.Journal of computer-aided molecular design · 2026Article
- Gobal, regional, and national burden of hepato-pancreato-biliary cancers in older populations, 1992-2021, and prediction to 2040: analysis of data from the Global Burden of Disease study, 2021.Journal of health, population, and nutrition · 2026Article
- Global, regional, and national burden of migraine in postmenopausal women: a 32-year analysis from the global burden of disease study 1990-2021.Journal of oral & facial pain and headache · 2026Article
- Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Global trends and projections of rehabilitation needs in chronic obstructive pulmonary disease, 1990-2050: an analysis using WHO rehabilitation need estimates.Frontiers in public health · 2026Article
- Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.Molecular medicine reports · 2026Article
- Burden and etiology of heart failure in mainland China from 1990 to 2021: Results from the GBD 2021 study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Comparative trends in pancreatic cancer burden and risk factors in the USA and China (1990-2021): insights from GBD analysis.BMC gastroenterology · 2025Article
- Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies.Journal of the Egyptian National Cancer Institute · 2025Review
- Burden of pancreatic cancer among the Western Pacific Region and association with human resources for health from 1990 to 2021: Results from the Global Burden of Disease Study 2021.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Spatiotemporal evolution of HCV burden among women of reproductive age: a multinational age-period-cohort analysis.Virology journal · 2025Article
- Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies.Journal of gastrointestinal oncology · 2025Article
- Spatiotemporal Dynamics in the Burden of Lip and Oral Cavity Cancer and Attributable Risk Factors in Asia (1990-2021).Healthcare (Basel, Switzerland) · 2025Article
- Other musculoskeletal disorders in China, 1990-2021, and projections to 2050: findings from the Global Burden of Disease Study 2021.Clinical rheumatology · 2025Article
- Hydrogel-mediated mitochondrial reprogramming for inducing cell death: a novel approach to overcoming gemcitabine resistance in pancreatic ductal adenocarcinoma.Materials today. Bio · 2025Article
- Article
- Lifestyle-Related Risk Factors for Pancreatic Ductal Adenocarcinoma: A Longitudinal Analysis of 1,120,377 Individuals From the NHISS Cohort.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveMetabolic risks play a key role in the progression of pancreatic cancer. This study aimed to present global, regional and national data on mortality and disability-adjusted life-year (DALY) for pancreatic cancer attributable to metabolic risk and to forecast mortality to 2030 using data from the Global Burden of Disease (GBD).
methodsData on mortality and DALYs due to pancreatic cancer attributable to metabolic risks were obtained from GBD 2019. Metabolic risks include high fasting plasma glucose (FPG) and high body mass index (BMI). Total numbers and age-standardized rates per 100,000 people for mortality and DALYs were reported by age, sex, region and country/territory from 1990 to 2019. The "Bayes age-period-cohort" method was used for projections of mortality to 2030.
resultsGlobally, there was a 3.5-fold increase in the number of pancreatic cancer deaths attributable to metabolic risk, from 22,091 in 1990 to 77,215 in 2019. High-income North America and Central Europe had the highest age-standardized mortality rates (ASMRs) of pancreatic cancer attributable to high FPG and high BMI in 2019, respectively. From 1990 to 2019, the global ASMR of pancreatic cancer attributable to high FPG and high BMI increased. Countries with high healthcare access quality had much higher age-standardized DALY rates. In the next 10 years, the ASMR of pancreatic cancer attributable to high FPG and high BMI will continue to increase.
conclusionPancreatic cancer mortality and DALYs attributable to metabolic factors remain high, particularly in high-income regions or countries. Studies on the metabolic mechanism of pancreatic cancer and effective treatment strategies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.